|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Background:</b> Metastatic prostate carcinoma over-expresses the prostate specific membrane antigen (PSMA) making this antigen a suitable target for radioligand therapy of the disease.
|
31101746 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The utility of PSMA-targeting imaging in metastatic prostate cancer appears to depend on patient disease course and treatment status.
|
29602821 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><sup>68</sup>Ga-PSMA-11 performed well for the localization of metastatic prostate cancer at initial staging and at the time of biochemical recurrence.
|
30530831 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>177</sup>Lu-DOTA-PSMA-617 (<sup>177</sup>Lu-PSMA-617) is a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioligand for radionuclide therapy (RNT) in PC.
|
31595044 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-DCFPyL is a small-molecule inhibitor of the prostate-specific membrane antigen that has shown promise for evaluation of primary and metastatic prostate cancer using PET.
|
27932557 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with <sup>223</sup>Ra: Proof of Concept.
|
27660148 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
68Ga-Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis.
|
31283614 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA), which is highly expressed in both localized and metastatic prostate cancer (PCa), is an ideal target for imaging and therapy of PCa.
|
28964633 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) PET has been recently introduced for the diagnosis of patients with metastatic prostate cancer (PCa).
|
29107272 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) PET/CT has a high diagnostic accuracy for lesion detection in metastatic prostate cancer, including bone metastases.
|
29242401 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) theranostics offers a new approach for a personalized and targeted treatment for metastatic prostate cancer.
|
29278583 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) is a receptor highly expressed on the membranes of prostate cancer (PCa) cells and provides a new opportunity for imaging and targeted therapy in metastatic prostate cancer.
|
30037209 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is highly overexpressed in primary and metastatic prostate cancer (PCa).
|
30656716 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer.
|
31644433 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A biopsy was performed, and histological examination revealed multiple myeloma with PSMA expression in the neovessels but no metastatic prostate cancer cells.
|
28737577 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 121 consecutive patients with recurrent PC as defined by PSMA-ligand PET (median PSA: 1.13ng/ml) underwent PSMA-targeted RGS.
|
30987843 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As metastatic prostate cancer progresses from castration-sensitive to castration-resistant, greater discordance is observed between NaF PET and PSMA PET uptake.
|
30701023 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
|
28719450 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early Detection of Metastatic Prostate Cancer Relapse on 68Ga-PSMA-11 PET/CT in a Patient Still Exhibiting Biochemical Response.
|
31693605 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifty-two patients with metastatic PCa who underwent [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT imaging and serum prostate-specific antigen (PSA) level measurements before and during treatment were investigated.
|
31468235 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ga-PSMA ligand PET/CT is a highly sensitive and specific imaging method for the detection of primary and metastatic prostate cancer and has refined diagnostic approaches.
|
28368893 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer.
|
29742609 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel imaging techniques, as multiparametric magnetic resonance imaging (MRI), whole-body MRI and Choline and prostate-specific membrane antigen (PSMA) PET imaging techniques are currently revolutioning the treatment planning in patients with advanced and metastatic PCa, allowing a better characterization of the disease.
|
29388415 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that <sup>68</sup>Ga-PSMA-11 PET should be combined with <sup>18</sup>F-NaF PET in PC patients with skeletal metastases for restaging prior to initiation or modification of therapy.
|
29766246 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that increase in PSMA in prostate tumors contributes to progression by altering normal signal transduction pathways to drive PCa progression and that enhanced signaling through the IGF-1R/β<sub>1</sub> integrin axis may occur in other tumors.
|
28292957 |
2017 |